Experimental Breast Cancer Drug Shows Potential to Treat Certain Blood Cancers
Two groundbreaking studies conducted by researchers at Washington University School of Medicine in St. Louis have identified a promising approach to halting the progression of several forms of blood cancer…
Ceasefire in Gaza Offers Hope Amidst Significant Challenges to Rebuild the Health System
The World Health Organization (WHO) has welcomed the recently brokered ceasefire in Gaza, along with the hostage and prisoner release agreement. This development offers a glimmer of hope for millions…
Medical Device Breakthrough WuXi AppTec to Strategically Sell U.S. Testing Operations to NAMSA
Impact on WuXi AppTec’s Operations WuXi AppTec, a global leader in providing comprehensive R&D and manufacturing services for the pharmaceutical and life sciences industries, recently announced the signing of a…
Groundbreaking Biomedical Collaboration Neuraly & Enigma Biomedical USA Partner on PET Imaging Biomarker PMI04
Biomedical Neuraly & Enigma Biomedical USA Partner on PET Imaging Biomarker PMI04 Neuraly, a biotechnology company specializing in the development of innovative treatments for neurodegenerative diseases, has entered into a…
FDA Approves Lilly’s Omvoh for Crohn’s Disease, Expanding Use in Inflammatory Bowel Disease
Eli Lilly and Company has announced that the U.S. FDA has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn’s disease in adults. This approval marks a…
WuXi Biologics CEO Dr. Chris Chen: Ready for Rapid Expansion
WuXi Biologics, delivered a keynote address at the 43rd J.P. Morgan Healthcare Conference, providing an insightful look into the company’s latest achievements, strategies, and future outlook. His presentation highlighted WuXi…
UCB Highlights a Decade of Growth and Patient-Centered Innovation Strategy
UCB is A global biopharmaceutical leader committed to improving the lives of people living with severe diseases, highlighted its decade of growth and strategic priorities at the 43rd J.P. Morgan…
Walgreens Resources for the ‘Quad-demic’ Vaccines, Treatments, and Support
Walgreens Steps Up Amid the ‘Quad-Demic’: Vaccines, Testing, Treatments, and Support The term “tripledemic” gained traction not too long ago to describe the simultaneous surges of flu, COVID-19, and respiratory…
Incyte and Syndax Announce FDA Approval of Niktimvo\u2122 (Axatilimab) in 9 mg and 22 mg Vials
Incyte and Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The companies expect the product to…
WHO Launches $1.5B Health Emergency Appeal
Unprecedented challenges such as conflict, climate change, epidemics, and displacement are converging to create a severe global health crisis, leaving 305 million people in dire need of humanitarian assistance in…
Orion Nomination Committee’s 2025 AGM Proposals
The Nomination Committee of Orion Corporation has provided its recommendations to the company’s Board of Directors regarding proposals for the 2025 Annual General Meeting (AGM). These recommendations address both the…
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802 Pheno Therapeutics Limited, a leading biotechnology company focused on developing small molecule therapeutics for neurological diseases, has received Clinical Trial…